Z3 Capital Partners’s Dyne Therapeutics DYN Stock Holding History

Z3 Capital Partners’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$305K	Hold	18,925	–	–	0.06%	147
2026 Q2	$420K	Sell	18,925 -200	-1%	-$3.72K	0.09%	128
2026 Q1	$347K	Buy	19,125 +4,075	+27%	+$70.3K	0.09%	135
2025 Q4	$294K	Buy	+15,050	New	+$285K	0.07%	148

Other funds holding DYN

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $631M AUM 38.42% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Z3 Capital Partners's DYN Position: Q3 2026 in Review

Z3 Capital Partners held its Dyne Therapeutics (DYN) position steady in Q3 2026 at 18,925 shares worth $305K. The position accounts for 0.06% of the portfolio, ranked #147.

Z3 Capital Partners first reported a position in DYN in Q4 2025 and has held it in 4 quarters since. The position peaked at $420K in Q2 2026. 179 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

Z3 Capital Partners held 18,925 shares of Dyne Therapeutics worth $305K as of Q3 2026.
Z3 Capital Partners left its Dyne Therapeutics share count unchanged in Q3 2026.
Dyne Therapeutics made up 0.06% of Z3 Capital Partners's portfolio in Q3 2026, its #147 holding.
Z3 Capital Partners first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 4 quarters since.
Z3 Capital Partners's Dyne Therapeutics position peaked at $420K in Q2 2026.
179 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Z3 Capital Partners's 13F filing for Q3 2026, filed 10 Nov 2026.